Vertex ousts COO Ian Smith over ‘personal behaviour’
January 24, 2019Business Services Ian Smith, Jobs, Vertex, executives
Boston-based firm Vertex Pharmaceuticals has fired Chief Operating Officer (COO) and interim Chief Financial Officer (CFO) Ian Smith. Smith’s termination, …
Irish Pfizer employees to launch industrial action ballot over pensions scheme
January 24, 2019Manufacturing and Production Ireladn, Pfizer, cork, industrial action, manufacturing, strike
Pfizer employees have rejected a Labour Court recommendation regarding their pension scheme, opting to initiate a ballot over potential industrial …
Cost of insulin doubled between 2012 and 2016
January 23, 2019Research and Development USA, healthcare, insulin, insurance, pricing
The cost of insulin almost doubled in the United States between 2012 and 2016, according to a report by the …
GSK acquires oncology firm Tesaro for $5.1 billion
January 23, 2019Research and Development Cancer, GSK, Tesaro, oncology, ovarian cancer
British multinational GlaxoSmithKline (GSK) have acquired US oncology firm Tesaro for $5.1 billion (£4 billion). Tesaro, a Massachusetts-based clinical stage …
NICE recommend digital CBT for young people with mild depression
January 23, 2019Research and Development CBT, Digital CBT, NHS, psychology, psychotherapy
Britain’s cost effectiveness body NICE has recommended digital Cognitive Behavioural Therapy (CBT) for children with mild depression as a first …
Amgen’s Blincyto secures expanded indication in Europe for acute lymphoblastic leukaemia
January 23, 2019Research and Development, Sales and Marketing Ammgen, Cancer, Europe, European Commission, blincyto, leukaemia, pharma
The European Commission has chosen to expand the authorised indication for Amgen’s Blincyto (blinatumomab) in the region, it has emerged, …
Including prices on TV ads only works when the price is listed alone
January 23, 2019Research and Development Trump, USA, pharma, pricing
Requiring pharmaceutical companies to publish the price of their drugs on adverts on TV, would probably not help to control …
FDA approves third Herceptin biosimilar with Samsung Bioepis’ Ontruzant
January 22, 2019Manufacturing and Production, Sales and Marketing FDA, Herceptin, Samsung Bioepis, biosimilar, pharma
Samsung Bioepis’ has announced that the FDA has chosen to approve Ontruzant (trastuzumab-dttb), its biosimilar version of Roche’s Herceptin (trastuzumab), …
Boehringer expands manufacturing facility in Shanghai
January 22, 2019Manufacturing and Production Boehringer Ingelheim, China, Shanghai, facilities, manufacturing, pharma
German firm Boehringer Ingelheim has expanded the capacity of its commercial manufacturing site for biologics in Shanghai, China. The expansion …
Scientist who genetically modified babies faces punishment after acting illegally, Chinese authorities confirm
January 22, 2019Manufacturing and Production China, He Jiankui, crispr, ethics, gene editing
Chinese state media have confirmed that He Jiankui, the scientist who claimed to have genetically modified babies to prevent them …
Vertex’s Orkambi can be used in even younger cystic fibrosis patients, says European Commission
January 22, 2019Manufacturing and Production, Sales and Marketing Orkambi, Vertex, cystic fibrosis, pharma
Vertex has announced that the European Commission has decided to approve a label extension in the region for Orkambi (lumacaftor/ivacaftor) …
AbbVie’s case against the NHS thrown out of court
January 22, 2019Manufacturing and Production AbbVie, HCV, NHS, health, hepatitis C, public health
A judge has thrown US multinational AbbVie’s case against NHS England’s hepatitis C procurement process, out of court. Mr Justice …
Pushing for progress in mesothelioma
January 21, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, mesothelioma, pharma
Mesothelioma.net reviews the wide array of latest advances in treatment and care for patients affected by the challenging cancer as …
Just 10% of those harmed in clinical trials in India receive compensation
January 21, 2019Sales and Marketing India, WHO, clinical trials, compensation, health
Clinical trials have led to nearly 5,000 deaths in India since 2005, while just a fraction of those affected have …
Lilly’s Lartruvo/chemo combo surprises with Phase 3 failure in soft tissue carcinoma
January 21, 2019Research and Development, Sales and Marketing Cancer, Eli Lilly, carcinoma, chemotherapy, pharma, trial failure
Eli Lilly has reluctantly pulled back the curtain on new Phase 3 data for its platelet-derived growth factor receptor alpha …
Celgene signs deals with two Massachusetts-based biotechs
January 21, 2019Sales and Marketing Celgene, Kyn, Obsidian, cell therapy, immuno oncology, immuno-oncology
New Jersey-based biotechnology firm Celgene has signed deals with two Massachusetts-based biotechs: immuno-oncology specialist Kyn therapeutics and cell therapy firm …
Philip Hampton to step down from chairman role at GSK
January 21, 2019Sales and Marketing Chairman, GSK, GlaxoSmithKline, appointment, philip hampton
Sir Philip Hampton is stepping down from his role as non-executive chairman of British multinational GlaxoSmithKline. The resignation comes just …
NICE recommends Pierre Fabre’s Braftovi in BRAF V600-mutated advanced melanoma
January 21, 2019Sales and Marketing Braftovi, Cancer, NICE, Pierre Fabre, UK, melanoma, pharma
Braftovi (encorafenib), a BRAF kinase inhibitor developed by Pierre Fabre, has been awarded approval in combination with Mektovi (binimetinib) by …
Sun Pharma’s shares hit six-year low after further whistleblower allegations emerge
January 18, 2019Medical Communications India, Sun Pharma, pharma
Sun Pharma has seen its shares fall by 12% to an almost six-year low after it was rocked by allegations …
Top Ten most popular articles on Pharmafile.com this week!
January 18, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Netherlands, Novo Nordisk, Roche, astra zeneca, prcing, sequiris, top 10, uk politics
Job switches were the theme of this week as AstraZeneca lost three, high levels executives to biotechs amid a restructuring …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
